Skip to main content

Table 3 Univariate and multivariate analyses of survival by baseline characteristics

From: Comprehensive molecular and clinical characterization of Asian melanoma patients treated with anti-PD-1 antibody

  PFS OS
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
HR p-value HR p-value HR p-value HR p-value
Age
<60 1 0.095    10.686 0.162   
≥60 0.722 (0.492–1.059)     (0.404–1.164)    
Performance status
 ECOG < 2 1 0.059 1 0.819 1 0.002 1 0.565
 ECOG ≥2 3.067 (0.957–9.836)   1.160 (0.325–4.132)   6.750 (2.068–22.026)   1.494 (0.381–5.858)  
Subtypes
 Mucosal 1 0.375    1 0.503  
 Cutaneous 1.182 (0.687–2.033) 0.400    0.954 (0.503–1.810) 0.885   
 Acral 1.221 (0.767–1.944) 0.545    1.130 (0.548–2.329) 0.741   
 Uveal 2.506 (0.877–7.157) 0.086    2.407 (0.703–8.243) 0.162   
Subtypes
 Non-cutaneous 11.233 0.329 11.045 0.879
 Cutaneous (0.810–1.879)     (0.591–1.848)    
M stage
 M1a 1 <0.001 1 0.001 1 <0.001 1 0.017
 M1b 1.751 (1.002–3.060) 0.049 2.032 (1.133–3.642) 0.017 1.830 (0.756–4.430) 0.180 1.769 (0.590–5.307) 0.309
 M1c 2.524 (1.466–4.344) 0.001 2.257 (1.279–3.984) 0.005 4.659 (2.109–10.294) <0.001 3.945 (1.075–14.474) 0.039
 M1d 4.495 (2.073–9.747) <0.001 5.167 (2.24–11.900) < 0.001 5.753 (2.142–15.451) 0.001 8.838 (2.192–35.626) 0.002
Bone metastasis
 No 1 0.005 1 0.280 1 0.011 1 0.108
 Yes 1.959 (1.219–3.149)   1.370 (0.775–2.422)   2.154 (1.190–3.898)   1.995 (0.860–4.629)  
Liver metastasis
 No 1 <0.001 1 0.644 1 <0.001 1 0.695
 Yes 2.228 (1.452–3.420)   0.835 (0.389–1.795)   3.687 (2.177–6.247)   0.795 (0.253–2.502)  
BRAFV600 status
 Wildtype 1 0.431 1 0.018 1 0.101
 Mutant 1.242 (0.724–2.133)     2.232 (1.150–4.330)   2.014 (0.872–4.655)  
KIT status
 Wildtype 1 0.888 1 0.333
 Mutant 1.052 (0.519–2.131)     1.557 (0.635–3.818)    
LDH
 Normal 1 0.001 1 0.035 1 <0.001 1 0.011
 Elevated 2.149 (1.361–3.393)   1.723 (1.039–2.860)   4.476 (2.512–7.974)   2.676 (1.248–5.736)  
NLR
 < 2.10 1 0.017 1 0.009 1 <0.001 1 <0.001
 ≥ 2.10 1.606 (1.090–2.367)   1.802 (1.160–2.799)   4.103 (2.243–7.504)   4.583 (2.121–9.907)  
  1. PFS progression-free survival, OS overall survival, NRL neutrophil/lymphocyte ratio, LDH lactate dehydrogenase concentration
  2. The numbers in boldface represented the values with statistical significance
\